840481-49-4

Basic information

• Product Name: 4-BroMo-2,6-difluorobenzaMide, 96%
• Synonyms: 4-BroMo-2,6-difluorobenzaMide, 96%
• CAS NO: 840481-49-4
• Molecular Formula: C₇H₄BrF₂NO
• Molecular Weight: 236.0135664
• Mol File: 840481-49-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-BroMo-2,6-difluorobenzaMide, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2,6-difluorobenzaMide, 96%(840481-49-4)
• EPA Substance Registry System: 4-BroMo-2,6-difluorobenzaMide, 96%(840481-49-4)

Safety Data

• Hazardous Substances Data: 840481-49-4(Hazardous Substances Data)

Usage

General Description

The chemical 4-Bromo-2,6-difluorobenzamide, 96% is a compound with a molecular formula C7H4BrF2NO. It is a white to light yellow solid with a purity of 96%. 4-BroMo-2,6-difluorobenzaMide, 96% is mainly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in research and development activities in various industries. 4-Bromo-2,6-difluorobenzamide, 96% is a versatile chemical that can be used in a wide range of applications due to its unique properties and composition.

Upstream product

• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 
• 461-96-1 3,5-difluorobromobenzene 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 

Downstream Products

• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 

Relevant articles and documents

Nitrile Hydration Reaction Using Copper Iodide/Cesium Carbonate/DBU in Nitromethane-Water

The catalytic nitrile hydration (amide formation) in a copper iodide/cesium carbonate/1,8-diazabicyclo[5.4.0]undec-7-ene/nitromethane-water system is described. The protocol is robust and reliable; it can be applied to a broad range of substrates with high chemoselectivity.

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.